<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00082524</url>
  </required_header>
  <id_info>
    <org_study_id>0991-043</org_study_id>
    <secondary_id>Formerly-0404CCAI</secondary_id>
    <secondary_id>MK0991-043</secondary_id>
    <secondary_id>2004_100</secondary_id>
    <nct_id>NCT00082524</nct_id>
  </id_info>
  <brief_title>Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043)</brief_title>
  <official_title>A Multicenter, Open-Label, Noncomparative Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in Children With Documented Candida or Aspergillus Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This study is an open label, noncomparative study using an investigational agent for the
      treatment of documented Candida or Aspergillus infections in pediatric patients (ages 3
      months-17 years).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients with one or more drug-related clinical or laboratory adverse experience(s)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who discontinued due to a drug-related AE or who have a serious drug-related AE</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with a favorable efficacy response to caspofungin therapy in each infection type</measure>
  </secondary_outcome>
  <enrollment type="Actual">50</enrollment>
  <condition>Aspergillosis</condition>
  <condition>Candidiasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caspofungin acetate</intervention_name>
    <description>Duration of Treatment - 7-90 days</description>
    <other_name>MK0991</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Children, 3 months through 17 years of age,

          -  with esophageal candidiasis or

          -  invasive candidiasis or

          -  children requiring salvage treatment of invasive aspergillosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Taiwan</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Zaoutis TE, Jafri HS, Huang LM, Locatelli F, Barzilai A, Ebell W, Steinbach WJ, Bradley J, Lieberman JM, Hsiao CC, Seibel N, Laws HJ, Gamba M, Petrecz M, Taylor AF, Strohmaier KM, Chow JW, Kartsonis NA, Ngai AL. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics. 2009 Mar;123(3):877-84. doi: 10.1542/peds.2008-1158.</citation>
    <PMID>19255017</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2004</study_first_submitted>
  <study_first_submitted_qc>May 12, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2004</study_first_posted>
  <last_update_submitted>February 20, 2017</last_update_submitted>
  <last_update_submitted_qc>February 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caspofungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSRSynopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

